Academic literature on the topic 'MET-HR'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'MET-HR.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "MET-HR"
1
Spigel, David R., Thomas J. Ervin, Rodryg A. Ramlau, Davey B. Daniel, Jerome H. Goldschmidt, George R. Blumenschein, Maciej J. Krzakowski, et al. "Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 31, no. 32 (November 10, 2013): 4105–14. http://dx.doi.org/10.1200/jco.2012.47.4189.
Full textAbstract:
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) –targeted drugs in patients with non–small-cell lung cancer (NSCLC). We investigated whether dual inhibition of MET/EGFR results in clinical benefit in patients with NSCLC. Patients and Methods Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. Tumor tissue was required to assess MET status by immunohistochemistry (IHC). Coprimary end points were progression-free survival (PFS) in the intent-to-treat (ITT) and MET-positive (MET IHC diagnostic positive) populations; additional end points included overall survival (OS), objective response rate, and safety. Results There was no improvement in PFS or OS in the ITT population (n = 137; PFS hazard ratio [HR], 1.09; P = .69; OS HR, 0.80; P = .34). MET-positive patients (n = 66) treated with erlotinib plus onartuzumab showed improvement in both PFS (HR, .53; P = .04) and OS (HR, .37; P = .002). Conversely, clinical outcomes were worse in MET-negative patients treated with onartuzumab plus erlotinib (n = 62; PFS HR, 1.82; P = .05; OS HR, 1.78; P = .16). MET-positive control patients had worse outcomes versus MET-negative control patients (n = 62; PFS HR, 1.71; P = .06; OS HR, 2.61; P = .004). Incidence of peripheral edema was increased in onartuzumab-treated patients. Conclusion Onartuzumab plus erlotinib was associated with improved PFS and OS in the MET-positive population. These results combined with the worse outcomes observed in MET-negative patients treated with onartuzumab highlight the importance of diagnostic testing in drug development.
2
Taminiau, Yvette, Stefan Heusinkveld, Claudia Visser, and Marlies Verschoor. "Strategisch HR-beleid van Big 4-accountantsorganisaties." Maandblad Voor Accountancy en Bedrijfseconomie 92, no. 3/4 (April 12, 2018): 111–24. http://dx.doi.org/10.5117/mab.92.23742.
Full textAbstract:
In dit exploratief onderzoek wordt geanalyseerd op welke wijze Big 4-accountantsorganisaties met hun HR-beleid strategisch reageren op de nieuwe wet- en regelgeving. Het onderzoek is gebaseerd op 24 diepte-interviews (merendeel met partners en HR-managers) binnen accountancy, consultancy en tax advisory. Uit ons onderzoek blijkt dat de gewijzigde wetgeving belangrijke implicaties heeft voor het HR-beleid op zowel korte als lange termijn. Tegelijkertijd laat het onderzoek zien dat de Big 4-accountantsorganisaties met dit HR-beleid een meer bureaucratische managementbenadering bevorderen in plaats van een benadering gebaseerd op professionaliteit. Deze meer bureaucratische benadering maakt het mogelijk om met hedendaagse institutionele druk om te gaan, maar zij creëert ook beperkingen voor het management van professionele organisaties.
3
Haluska, F. G., A. Y. Bedikian, A. C. Pavlick, M. Millward, M. Gore, H. Pehamberger, U. Trefzer, and A. Eggermont. "Oblimersen in combination with dacarbazine prolongs prognostic factor-adjusted overall survival." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 18006. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.18006.
Full textAbstract:
18006 Backgound: In a stratified randomized study comparing dacarbazine (DTIC) and oblimersen (Obl) with DTIC alone in metastatic melanoma, overall survival (OS) was increased in the Obl+DTIC group (P = .077). We report results from a multivariate analysis, including prognostic factors. Methods: The study enrolled 771 patients; 2.2% data were missing. Stratification factors included elevated LDH (>1.1 ULN), performance status (PS) >0, and metastatic site (MET): MET A = liver, MET B = other visceral, MET C = skin, subcutaneous, or lymph nodes only. Each stratification factor was evaluated using monovariate analysis for treatment interaction. Cox model included treatment, any identified factor, gender, or interaction term for OS and progression-free survival (PFS), and a logistic regression for response rate (RR). Results: The stratification factor with the greatest impact on survival was elevated LDH (HR 2.212, P < .0001), followed by PS > 0 (HR 1.497, P < .0001), MET A (HR 1.456, P < .0001), and MET C (HR 0.670, P < .0004). Interaction significance between treatment and LDH, PS, MET A, and MET C were 0.023, NS (0.279), NS (0.419), and NS (0.329), respectively. MET B was used as the reference category for MET A and MET C. Conclusion: As expected, all stratification factors were prognostic, with LDH being the most important factor (HR 2.2). The addition of Obl to DTIC treatment improved outcomes for all efficacy end points. A statistical interaction between Obl treatment and LDH was found for survival. Multivariate analysis was significant in all efficacy end points. Patients with abnormal baseline LDH, already understood to have a poor prognosis, were unlikely to benefit from this therapy and should not be included in future trials of combination oblimersen treatments. [Table: see text] No significant financial relationships to disclose.
4
Dahlrot, Rikke Hedegaard, Stine Asferg Petterson, Simon Kjaer Hermansen, Bjarne Winther Kristensen, and Steinbjorn Hansen. "C-met, a new prognostic biomarker in glioblastoma multiforme." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 2088. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.2088.
Full textAbstract:
2088 Background: C-met is a tyrosine kinase receptor involved in growth, invasiveness and malignant progression in glioblastoma multiforme (GBM). Activation of the C-met pathway increases resistance towards DNA damage in glioma cell lines and it has been shown that an orally administrated C-met kinase inhibitor inhibits intracranial glioma growth in immunodeficient mice, suggesting that C-met is a potential target in glioma treatment. The purpose of the present study was to investigate the prognostic value of C-met in GBMs and subsequently correlate the prognostic value to known clinical variables, identified in a population-based cohort. Methods: Tissue samples from 186 GBM patients were analyzed using immunohistochemical staining and advanced quantitative image analysis. This provided continuous measurements based on staining intensity. Results: Median intensity was 70.8 (range 15.5-200.1). When divided at the median C-met was not prognostic. Further exploration showed that dichotomizing at an intensity of 75 (60% vs. 40%), high levels of C-met were associated with poor survival. However; C-met is a time-dependent factor and no prognostic effect was observed within the first 8.5 months after diagnosis (HR 0.97, 95% CI 0.62-1.51, p = 0.892). After 8.5 months, patients with high levels of C-met had a significantly poorer survival as compared to patients with low levels (HR 2.06, 95% CI 1.33-3.18, p = 0.001). This was significant in multivariate analysis adjusted for clinical variables; C-met (HR 1.89, 95% CI 1.22-2.93, p = 0.004), age (HR 1.02, 95% CI 1.00-1.03, p = 0.037), performance status (HR1.55, 95% CI 1.38-1.74, p = 0.004), and tumor crossing midline (HR 1.72, 955 CI 0.75-3.92, p = 0.201). Interestingly; C-met was only prognostic in patients who received post-surgical treatment, whereas no effect was observed in the 31 patients who underwent surgery only (HR 0.54, 95% CI 0.26-1.15, p = 0.113). Conclusions: Using advanced quantitative image analysis, we found that C-met was an independent prognostic factor of poor survival in GBMs. The effect did not appear within the first 8.5 months after the diagnosis and it was only seen in patients who received post-surgical treatment.
5
Pietrasz, Daniel, Shufang Wang-Renault, Laetitia Dahan, Julien Taieb, Karine Le Malicot, Yves Rinaldi, Solene Doat, et al. "Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 4136. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4136.
Full textAbstract:
4136 Background: Circulating tumor DNA has emerged as prognostic biomarker in oncology. Many different genes can be mutated within a tumor, complicating procedures, even with highly sensitive next-generation sequencing (NGS). DNA methylation in promotor of specific genes is an early key epigenetic change during oncogenesis. Specific methylated genes could be a potential relevant cancer biomarker that may substitute for NGS panels. The aim of this study was to assess the prognostic value of Met-DNA in mPAC. Methods: Prognostic value of Met-DNA was assessed in a prospective cohort (PLAPAN) of mPAC (training cohort), correlated with NGS, then in two prospective independent validation cohorts from two randomized phase II trials (PRODIGE 35 and 37). Plasma samples were collected before chemotherapy on EDTA-coated tubes. Met-DNA was quantified using two specific markers of pancreatic DNA methylation by digital droplet PCR and correlated with prospectively registered patient (pts) characteristics and oncologic outcomes (progression free survival (PFS) and overall survival (OS)). Results: 330 patients (pts) were enrolled. 60% (n = 58) of the 96 pts of the training cohort had at least one Met-DNA marker. The correlation with NGS assessment was R = 0.93 (Pearson; p < 0.001). 59.5% (n = 100/168) and 59% (n = 39/66) of pts had detectable Met-DNA in the 2 validation cohorts. In the training cohort, Met-DNA was correlated with poor OS (HR = 1.82; 95%CI 1.07-2.42; p = 0.026). In validation cohorts, Met-DNA was a prognostic factor of PFS (HR = 1.62; 95%CI 1.17-2.25, p = 004) and OS (HR = 1.79; 95%CI 1.28-2.49, p < 0.001) in PRODIGE 35, as in PRODIGE 37: PFS HR = 1.79 (95%CI 1.07-2.99; p = 0.026) and OS HR = 2.08 (95%CI [1.18-3.68], p = 0.01), respectively. In multivariate analysis adjusted on gender, age, CA19-9 > 40UI.mL, treatment arm, number of metastatic sites and stratified on center, Met-DNA was independently associated with poor OS in both trials: HR = 1.81 (95%CI 1.10-2.98; p = 0.02) and HR = 3.62 (95%CI: 1.32-9.93; p = 0.01). Conclusions: This study demonstrates that Met-DNA is a strong independent prognostic factor in mPAC. These results argue for patient’s stratification on ctDNA status for further randomized trials. Clinical trial information: NCT02827201 and NCT02352337.
6
Bendell, Johanna C., Howard S. Hochster, Lowell L. Hart, Irfan Firdaus, Joseph Ronald Mace, Joshua Jemison McFarlane, Mark Kozloff, et al. "A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 663. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.663.
Full textAbstract:
663 Background: In mCRC, MET overexpression has been associated with poor prognosis and resistance to anti-VEGF therapy. We initiated a phase II study to evaluate the combination of onartuzumab (O), a ligand-blocking monoclonal antibody directed against the MET receptor, plus bevacizumab and FOLFOX, in first-line mCRC (GO27827; NCT01418222). Methods: This double-blind, randomized, multicenter phase II study randomized patients 1:1 to receive O (10 mg/kg iv) or placebo (P), plus mFOLFOX6 and bevacizumab (5 mg/kg iv). Stratification was by prior adjuvant therapy. All treatments were given on day 1–3 of a 2-week cycle. Oxaliplatin was given for up to 8–12 cycles; all other agents were continued until progression, unacceptable toxicity or death. Primary endpoint was progression-free survival (PFS) in ITT and MET+ subgroup by immunohistochemistry (IHC). MET status was determined by central laboratory IHC evaluation, with scores of 2+ or 3+ considered MET+. Results: From September 2011 to November 2012, 194 patients were enrolled. A recommendation was made to stop O after an interim efficacy and safety analysis in September 2013, due to lack of efficacy. The final analysis (cut-off Feb 2014) found that O did not improve PFS vs. P in the ITT (HR 0.75 [0.52–1.08]; p=0.12) or MET IHC+ populations (n=79; HR 1.03 [0.56–1.89]; p=0.93), although improvement was noted in the MET IHC− population (n=108; HR 0.60 [0.37–0.97]; p=0.03). Neither overall survival (OS) nor response rate (RR) was improved with O vs. P in any of the groups (OS HR 0.96 [0.61–1.50], p=0.85 for ITT; OS HR 1.24 [0.63–2.43], p=0.54 for MET IHC+; OS HR 0.83 [0.44–1.56], p=0.56 for MET IHC−; RR 57.3% vs. 57.7% for ITT, 43.2% vs. 57.1% for MET IHC+, 66.1% vs. 60.8% for MET IHC−). More edema (65.7% vs. 12.9%) and venous thromboembolic events (30.3% vs. 16.1%) were seen with O vs. P, respectively. Grade ≥3 events were similar (86.9% vs. 84.9%) and events leading to discontinuation were increased (48.5% vs. 37.6%) with O vs. P. Conclusions: Adding onartuzumab to FOLFOX/bevacizumab did not prolong PFS in first-line unselected or MET IHC+ mCRC. A trend towards PFS benefit was seen in those with MET IHC− mCRC, contrary to prior reports in other tumor types. Clinical trial information: NCT01418222.
7
LEE, MIYOUNG, WEIMO ZHU, BRAD HEDRICK, and BO FERNHALL. "Estimating MET Values Using the Ratio of HR for Persons with Paraplegia." Medicine & Science in Sports & Exercise 42, no. 5 (May 2010): 985–90. http://dx.doi.org/10.1249/mss.0b013e3181c0652b.
Full text
8
Keizman, Daniel, Maya Ish-Shalom, Avivit Peer, Maya Gottfried, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, et al. "Metformin use and outcome of sunitinib treatment in diabetic patients with metastatic renal cell carcinoma." Journal of Clinical Oncology 33, no. 7_suppl (March 1, 2015): 440. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.440.
Full textAbstract:
440 Background: Sunitinib (Su) is a standard treatment (tx) for metastatic renal cell carcinoma (mRCC). Pre-clinical and clinical studies in several cancer types suggest that the antidiabetic agent metformin (Met) has antitumor activity. Met may negatively regulate mTOR activity. Its effect on the outcome of targeted therapies in mRCC is poorly defined. We analyzed the effect of Met use on the outcome sunitinib tx in diabetic patients (pts) with mRCC. Methods: We performed a retrospective study of an unselected cohort of diabetic pts with mRCC, who were treated with Su in 7 centers across 2 countries. Pts were divided into 2 groups: (1) Met users and (2) Met naive. The effect of Met use on response rate (RR), progression free survival (PFS) and overall survival (OS), was tested with adjustment of other known confounding risk factors using a chisquare test and partial likelihood test from Cox model. Furthermore, univariate and multivariate analyses of association between clinicopathologic factors and Met use, and outcome were performed using the entire pt cohort. Results: Between 2004-2014, 108 diabetic pts with mRCC were treated with sunitinib. There were 52 Met users (group 1) and 56 nonusers (group 2). The groups were balanced regarding the following clinicopathologic factors: age, gender, HENG risk, past nephrectomy, mRCC histology, ≥2 metastatic sites, lung/liver/bone metastasis, prior targeted tx, smoking status, use of angiotensin system inhibitors (ASIs), pre-tx neutrophil to lymphocyte ratio (NLR) >3, Su-induced hypertension (HTN), and Su dose reduction/tx interruption. Clinical benefit (partial response + stable disease) in group 1 vs. group 2 was 96% vs. 84%, while 4% vs. 16% had disease progression within the first 3 months of tx (p=0.054). Median PFS was 15 vs. 11.5 months (p=0.1). Median OS was 32 vs. 21 months (p=0.001). In multivariate analyses of the entire pt cohort (n=108), factors associated with PFS were active smoking (HR=2.7, p<0.0001) and pre-tx NLR >3 (HR 1.8, p=0.012). Factors associated with OS were Met use (HR 0.2, p<0.0001), HENG risk (HR 3.3, p=0.008), active smoking (HR=2.9, p<0.0001), liver metastases (HR 1.8, p=0.004), and pre-tx NLR >3 (HR 3.3, p<0.0001). Conclusions: Met use may improve the OS of diabetic pts with mRCC that are treated with Su.
9
Teufel, Michael, Karl Köchert, Gerold Meinhardt, and Jordi Bruix. "Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 4078. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4078.
Full textAbstract:
4078 Background: REG is a multikinase inhibitor which improved overall survival (OS; HR 0.63, 95% CI 0.50, 0.79; P<0.0001) and time to progression (TTP; HR 0.44, 95% CI 0.36, 0.55; P<0.0001) compared with placebo in patients with HCC who progressed during prior sorafenib treatment in the RESORCE trial. This exploratory analysis evaluated the impact of baseline AFP and c-Met on REG treatment benefit (OS and TTP) in the RESORCE trial. Methods: Circulating AFP and c-Met protein (shed ectodomain) levels were quantified by a Luminex assay (Myriad RBM) in plasma samples collected at baseline from patients enrolled in the RESORCE trial. Valid biomarker data were available from 497 (AFP) and 499 (c-Met) out of 573 patients. Patients were subgrouped according to the median protein concentration (high vs low), and the treatment effect HR and its 95% CI were evaluated using a Cox proportional hazards model. The predictive effect was modeledas a protein–treatment interaction effect and subjected to Akaike information criterion (AIC)-based selection to assess its association with OS and TTP. Results: Baseline characteristics of patients were balanced across protein subgroups. While increased levels of both AFP (HR 1.09, 95% CI 1.07, 1.12; P<0.001) and c-Met (HR 1.32, CI 95% 1.06, 1.63; P=0.011) were associated with a worse prognosis for OS, increased AFP levels were also associated with poor prognosis for TTP (HR 1.05, 95% CI 1.03, 1.07; P<0.001). REG treatment benefit for both OS and TTP was independent of AFP and c-Met protein expression (Table). The protein–treatment interaction effect was not statistically significant. Conclusions: The treatment benefit of REG in patients with HCC was independent of AFP and c-MET protein expression at baseline. So far, no single protein has been associated with REG clinical benefit. Clinical trial information: NCT01774344. [Table: see text]
10
Adeel, Muhammad, Chien-Hung Lai, Chun-Wei Wu, Jiunn-Horng Kang, Jian-Chiun Liou, Hung-Chou Chen, Bor-Shing Lin, Meng-Jyun Hong, Chun-Ta Feng, and Chih-Wei Peng. "Modeling of Metabolic Equivalents (METs) during Moderate Resistance Training Exercises." Applied Sciences 11, no. 18 (September 21, 2021): 8773. http://dx.doi.org/10.3390/app11188773.
Full textAbstract:
Energy expenditure through metabolic equivalent (MET) prediction during resistance exercises in humans can be modeled by using cardiorespiratory parameters. In this study, we aimed to predict MET during six moderate-intensity resistance training sessions consisting of three different exercises. Eleven participants were recruited into two groups; an untrained (n = 5; with no resistance training experience) and a trained group (n = 6; with 2 months resistance training experience). Each participant completed six training sessions separated with a rest interval of 1–2 days. While wearing a mask for indirect calorimetric measurements using Cortex Metalyzer 3B, each participant performed training sessions consisting of three types of dumbbell exercises: shoulder press, deadlift, and squat. The metabolic equivalents (METs), respiratory exchange ratio (RER), heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), blood lactate (BL), and Borg rate of perceived exertion (RPE) were measured. The MET was predicted using generalized estimating equations (GEE) for repeated measure data collected during exercise and rest periods. It was observed that during exercise period, RER, HR, SBP, and BL for the training group (QIC = 187, 95% CI = −0.012~0.915, p = 0.000*~0.033*) while RER, HR, SBP, DBP, and RPE (QIC = 48, 95% CI = −0.024~0.422, p = 0.000*~0.002*) during resting period for untrained group significantly predicted MET for moderate-intensity interval resistance training. It is concluded that the cardiorespiratory variables are significantly related to MET. During exercise, RER and HR significantly predicted MET for both groups along with additional parameters of SBP and BL for the training group. While during the resting period, RER, HR, SBP, DBP, and RPE related significantly for untrained and BL for training group respectively.
Dissertations / Theses on the topic "MET-HR"
1
Guillaume, Damien. "Etude expérimentale du système fer - smectite en présence de solution à 80°C et 300°C." Phd thesis, Université Henri Poincaré - Nancy I, 2002. http://tel.archives-ouvertes.fr/tel-00007672.
Full textAbstract:
Dans la perspective de prédire les transformations chimico-minéralogiques possibles d'une bentonite placée en conditions de stockage profond de déchets radioactifs, plusieurs séries d'expériences ont été réalisées utilisant la bentonite MX80 en présence d'une solution chlorurée sodi-calcique, en absence ou en présence de fer (magnétite + hématite ou fer métal + magnétite), à 80 et 300 °C et pour des durées de 1 jour à 9 mois. Les produits de réactions ont fait l'objet de caractérisations multi-échelles et multi-techniques : diffraction des rayons X, microscope électronique à balayage et en transmission (imagerie haute résolution, EDS et EELS), microsonde électronique, spectroscopie Mössbauer et analyse ICP AES et ICP MS des solutions. Le code de calcul EQ3/6 a été utilisé pour simuler les expériences réalisées. Une nouvelle méthode ponctuelle de détermination de la valence du fer dans les argiles au MET par spectroscopie de perte d'énergie des électrons (EELS) a été développée.
2
Huang, Botao. "Mécanismes de vieillissement de l'Assemblage-Membrane-Électrodes dans une pile à combustible de type PEM par approche expérimentale." Thesis, Université de Lorraine, 2012. http://www.theses.fr/2012LORR0268/document.
Full textAbstract:
Cette thèse a permis de mettre en évidence les mécanismes de vieillissement de la pile à combustible de type PEM lors de cyclages d'humidité de l'air et suite à la perforation de l'AME (Assemblage Membrane Electrodes). Premièrement, les mécanismes connus de dégradation des divers composants (membrane, catalyseur, support du catalyseur, GDL, plaques bipolaires et joints d'étanchéité) ont été présentés. Ensuite, les outils de diagnostic en-ligne (chronopotentiométrie, spectroscopie d'impédance, gestion de l'eau et analyse chimique de l'eau) et ceux hors-ligne (CV et LSV) ainsi que des analyses post-mortem (RMN, MET, MEB et DRX) ont été décrits. Expérimentalement, le cyclage en humidité de l'air a été effectué en mono-cellule de 25 cm2: le cyclage à forte humidité entraîne une perte significative de la surface électroactive du catalyseur; le cyclage à faible humidité favorise la perméation de l'hydrogène à travers la membrane. Le cyclage à faible humidité réalisé sur une pile de 100 cm2 a montré un mécanisme de dégradation différent de celui de la pile de 25 cm2: la perméation de l'hydrogène reste faible alors que la tension de la pile était de plus en plus fluctuante certainement du fait de la présence de volumes morts et de la rétention d'eau liquide dans la pile. L'effet de la perforation de l'AME a été étudié sur une pile de 100 cm2: la perforation par une punaise de 0,7 mm de diamètre ne génère qu'une légère augmentation de la perméation de l'hydrogène; la perforation par une punaise de 1,2 mm de diamètre entraîne une chute de tension et l'augmentation significative de la résistance de diffusion de l'oxygène due à la perméation importante de l'hydrogèneThis thesis highlights the aging mechanisms of PEM Fuel Cell submitted to two main aging conditions: air relative humidity (RH) cycling, and MEA (Membrane Electrode Assembly) pinhole test of operation. First, the aging mechanisms of PEMFC main components (membrane, catalyst, carbon support, GDL, bipolar plates and gaskets), have been reviewed from the literature. Then the on-line diagnostic tools (chronopotentiometry, electrochemical impedance spectroscopy, water management and water analysis), off-line ones (cyclic voltammetry and linear sweep voltammetry) and post-mortem analyses (nuclear magnetic resonance, transmission electron microscopy, scanning electron microscopy and X-ray diffraction) have been described. Experimentally, the high and low air RH cycling runs have been carried out with a 25 cm2 single cell: the high air RH cycling run promoted serious loss of the ElectroChemical Surface Area (ECSA); the low air RH cycling run caused significant increase in hydrogen crossover. The low air RH cycling has been also performed with a 100 cm2 single cell and the aging mechanism was different from that of 25 cm2 cell: the hydrogen crossover remained very low but the fuel cell voltage exhibited strong fluctuations at the end of the run: this was attributed to the presence of dead volumes and liquid water retention within the cell. Finally, MEA pinhole effect has been investigated with a 100 cm2 single cell: the perforation by a 0.7 mm diameter pin promoted slight increase in the hydrogen crossover; the perforation by a 1.2 mm diameter pin caused significant cell voltage losses and serious increase in the cathode diffusion resistance due to significant hydrogen crossover
Book chapters on the topic "MET-HR"
1
Yeh, Shao-Wei, Mei-Jung Chen, Cheng-Tien Chuang, and Wen-Bin Lin. "Performance Evaluation of Teams in Chinese Professional Baseball League." In Research Anthology on Business Strategies, Health Factors, and Ethical Implications in Sports and eSports, 816–30. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-7707-3.ch045.
Full textAbstract:
In this article, a performance evaluation of the Chinese Professional Baseball League (CPBL) was conducted from a human resources (HR) perspective. Two important aspects were included: (1) a comprehensive evaluation of the competition performance of the professional baseball teams in international games and regular season games; and (2) the data envelopment analysis (DEA) and “two-stage” methodologies, which were employed to process truncated data to resolve the factors that affect the efficiency of the decision-making unit (DMU). By applying DEA and truncated regression analysis with bootstrapping, the performances of CPBL teams in games of different intensities were investigated. The number of foreign coaches and native players both were the key factors to affect the competitive efficiency of CPBL teams, and the Uni President 7-ELEVEN Lions had the best performance efficiency team. This interdisciplinary investigation provided the most appropriate references and recommendations for professional baseball teams on HR management so that baseball fans' expectations are met.
2
Russo, Barbara, Marco Scotto, Alberto Sillitti, and Giancarlo Succi. "Discontinous use of Pair Programming." In Agile Technologies in Open Source Development, 256–67. IGI Global, 2010. http://dx.doi.org/10.4018/978-1-59904-681-5.ch014.
Full textAbstract:
Pair Programming (PP) has usually considered non effective for distributed teams, not working most of the time together (Williams et al., 2000; Baheti et al., 2002). In this chapter we discuss the effectiveness of PP at transferring knowledge and skills among students that met only occasionally and worked mostly independently. The effect of geographical distance between pair programmers has been already addressed by Baheti et al. (2002). They performed an experiment on a graduate class to assess whether it is feasible to use distributed PP to develop software. It turned out that distributed (i.e., geographically distant) pair programming teams can effectively develop software, that is, with productivity (in terms of LOC/hr) and code quality (in terms of grade awarded to the project developed) comparable to those of close-knit teams.
Conference papers on the topic "MET-HR"
1
Chen, Junhua, Mark G. Mitchell, and John G. Nourse. "Development of Ultra-Low Emission Liquid Fuel-Fired Microturbine Engines for Vehicular Heavy Duty Applications." In ASME Turbo Expo 2009: Power for Land, Sea, and Air. ASMEDC, 2009. http://dx.doi.org/10.1115/gt2009-60257.
Full textAbstract:
Worldwide regulations currently set very stringent emissions standards for new on-road heavy-duty diesel engines (HDDE’s). For example, the United States Environmental Protection Agency (EPA) and the California Air Resources Board (CARB) require 2010 and subsequent HDDE and vehicles to emit less than 0.2 g/bhp-hr (0.27 g/kW-hr) NOx and 5.0 g/bhp-hr (6.7 g/kW-hr) CO in addition to other strictly regulated pollutants. Diesel or biodiesel fired Microturbine engines are in use in hybrid electric vehicular (HEV) urban bus applications because of their extremely low emissions. In Capstone’s model years 2001 through 2003, liquid fueled gas turbines were certified by CARB for on-road heavy duty engine use, including urban bus applications. The engines achieved a low emission level of 0.7 g/hp-hr (0.94 g/kW-hr) NOx, 0.2 g/hp-hr (0.27 g/kW-hr) CO and 0.01 g/hp-hr (0.013 g/kW-hr) PM, which met emissions compliance levels for EPA and CARB regulations until 2010. To meet the upcoming 2010 EPA and CARB HDDE regulations, continuous research and development efforts have been taken at Capstone Turbine Corporation for its C30 family engines to further reduce the criteria pollutant emissions. Pollutant emissions were measured and analyzed for a Capstone C30 engine using ultra low sulfur diesel (ULSD) and five other opportunity fuels to obtain their actual cycle emissions for a typical New York City M60 route. By injector modification alone, the C30 engine was able to achieve 62% reduction in NOx emission. Additionally, an adjustment of turbine exit temperature was able to further reduce NOx. It was predicted that the liquid-fueled C30 engines would be able to demonstrate the compliance to the 2010 EPA/CARB new ultra-low emission standards.
2
Savelli, J. F., and G. L. Touchton. "Development of a Gas Turbine Combustion System for Medium-BTU Fuel." In ASME 1985 International Gas Turbine Conference and Exhibit. American Society of Mechanical Engineers, 1985. http://dx.doi.org/10.1115/85-gt-98.
Full textAbstract:
The Cool Water Coal Gasification Project requires a gas turbine combustion system to burn a high hydrogen medium-Btu coal gas produced in an oxygen-blown gasifier. The gas turbine selected for this demonstration plant is a General Electric Company MS7001E unit. The plant is located in Daggett, California, a location requiring compliance with stringent environmental regulations; that is, oxides of nitrogen (NOx) at 63.5 kg/hr and carbon monoxide (CO) at 35.0 kg/hr in the machine exhaust. The plant operating configuration requires fuel gas to be supplied at 330 °K and 477 °K with 20%/vol moisture blended. A combustion system was developed enabling the gas turbine to operate from full speed no load to full load on both fuel gas configurations. Distillate oil capability was also incorporated to facilitate safe machine startup and shutdown. Emissions requirements for NOx were met with steam injection, “CO” by combustor design, and sulfur oxides are met by fuel gas cleanup. A conventional combustion liner sleeve with a standard air admission schedule was used. A unique fuel nozzle, based upon past low-Btu fuel work, was designed incorporating the latest low erosion oil nozzle. One combustor of the 10 fitted to an MS7001E was tested at full pressure and airflow. Test results indicate, as predicted analytically, that NOx prediction varies substantially between cold dry fuel gas and hot wet gas. NOx compliance was attainable with little degradation of other design considerations. Carbon monoxide emissions were well below the required limits.
3
Bannister, R. L., B. C. Wiant, R. C. Diehl, H. M. Eppich, A. R. Jensen, F. V. Mach, E. U. Claeson, L. M. Raatikka, and R. A. Newby. "Development of a Direct Coal-Fired Combined Cycle for Commercial Application." In ASME 1992 International Gas Turbine and Aeroengine Congress and Exposition. American Society of Mechanical Engineers, 1992. http://dx.doi.org/10.1115/92-gt-258.
Full textAbstract:
A program has been underway since 1986 by Westinghouse Electric Corporation, Textron, Inc., and the sponsoring agency, the Morgantown Energy Technology Center (METC) of the U.S. Department of Energy (DOE), as participants, to establish the technology base for coal-fired combustion turbines targeted for power generation (50 to 150 MW size units). The developed system must be able to burn unbeneficiated, low-cost, utility-grade coal and meet the EPA New Source Performance Standards (NSPS) for coal-fired steam generators (Thoman et al., 1987). Development of a high pressure (12 to 16 atms) slagging combustor is the key to making a direct coal-fired combustion turbine a commercial reality. In testing to date, a 6 atm slagging combustor, rated at 12 MMBtu/hr (12.7 MHkJ/hr) has demonstrated its ability to handle high- and low-sulfur bituminous coals, and low-sulfur subbituminous coal. The program objectives relative to combustion efficiency, combustor exit temperature and pattern factor, NOx emissions, carbon burnout, and slag rejection have been met. Today, Northern States Power, working with Westinghouse with assistance from Textron is developing a plan to commercialize a direct coal-fired advanced combined cycle (DCFACC). Included in this plan is a pilot plant (which does not include a combustion turbine) and a demonstration plant that would utilize a 50 MW combustion turbine. The first commercial DCFACC, which would Include a 100 MW combustion turbine, is scheduled to be operational by the year 2001. The cooperative effort among Northern States Power, Westinghouse, and Textron is financially independent of the work now sponsored by DOE/METC. This paper presents the status of the pressurized slagging combustor development program including recent work to reduce alkali, particulates and SOx levels leaving the combustor and gives an overview of our commercialization process and plan.
4
Freen, Paul D., Jess Gingrich, and James Chiu. "Combustion Characteristics and Engine Performance of a New Radio Frequency Electrostatic Ignition System Igniting Lean Air-Fuel Mixtures." In ASME 2004 Internal Combustion Engine Division Fall Technical Conference. ASMEDC, 2004. http://dx.doi.org/10.1115/icef2004-0853.
Full textAbstract:
Recently, industry and government have joined together to develop high efficiency, low emissions, natural gas fueled, industrial, reciprocating engines for power generation. The California Energy Commission targets fuel-to-electricity efficiency at over 50% and NOx less than 0.01 gm/BHP-hr by the year 2010 [1]. The Department of Energy’s ARES program has targeted 50% efficiency and 0.1 gm/BHP-hr NOx by 2010 [2]. The engine manufacturers have determined that these goals cannot be met with current ignition system technology. They have jointly developed a specification for the next generation ignition system [3], which will support meeting the engine cost, efficiency and emissions goals. The Electrically Controlled Combustion Optimization System (ECCOS) is a new technology (patent pending) which is designed to meet or exceed this specification. This ignition system generates a high voltage, low current, radio frequency electrostatic field inside the combustion chamber to efficiently ionize the air and fuel mixture and initiate multiple flame fronts. The system is able to reliably introduce much higher ionization energy to the combustion chamber than conventional ignition systems because the ionization is done with a high voltage electric field, not high temperature. Conventional ignition systems generate up to 30,000 deg F of temperature in the spark plug gap. This temperature is created in the plug gap by a high current, low voltage plasma arc. The reliance of the conventional ignition system on temperature to initiate combustion limits the maximum energy that can be delivered because the high temperatures erode the electrodes. Since the ECCOS does not generate these high temperatures, electrode erosion should not be a problem. This paper presents a comparison of combustion characteristics between a conventional ignition system and the ECCOS igniting various mixture rations of propane and air in a constant volume combustion test chamber. Pressure rise rates as well as combustion photographs of the ignition and flame propagation processes are presented. In addition, experimental data obtained from the natural gas, single-cylinder engine operating with a conventional ignition system and the ECCOS are presented. Combustion rates, ignition delay, fuel consumption and emissions are presented at various air-fuel ratios.
5
Noordin, M. Farriz, Sylvia Mavis James Berok, Haydn Brent Sinanan, M. Farhan Suratman, Oka Fabian, M. Afzan Mohammad, and M. Raimi Johari. "Successful Deployment of 15Cr OCTG CRA Injection Tubing in Immiscible Water-Alternating-Gas iWAG Wells - First in the World." In International Petroleum Technology Conference. IPTC, 2021. http://dx.doi.org/10.2523/iptc-21477-ms.
Full textAbstract:
Abstract PETRONAS has undertaken a large EOR project offshore Malaysia involving the use of Immiscible Water-Alternating-Gas (iWAG) wells for fluid injection. These iWAG injection wells will allow the alternate injection of both treated seawater and hydrocarbon gas. A significant concern for these wells is tubing corrosion resistance and integrity for over a 25-year injection life. The initial conceptual design for the iWAG injection tubing utilized Glass Reinforced Epoxy (GRE) & 25Cr tubing material due to the presence of dissolved oxygen in the injected water. The use of these materials present challenges due to limitations in downhole flow device installation with the GRE tubing and high cost of 25Cr tubing. The project team searched for alternative, fit for purpose materials to meet the project's requirements. Based on the recent PETRONAS success case of 17Cr utilization, the team examined the possibility of using 17Cr or lower grade CRA material for injection purposes. By pioneering the first application of 15Cr OCTG as an iWAG injection tubing material in the world, several risks had to be considered. Additionally, all risks had to be mitigated via various approaches ranging from detailed engineering planning to field execution and operation. The process of selecting this metallurgy involved criteria such as cost, performance, manufacturability and operational execution. The selection methodology included a comprehensive evaluation and recommendation process that consisted of: Evaluation of currently used metallurgical properties and limitations Identification of alternatives based on operating conditions, cost and manufacturing constraints Metallurgy qualification through comprehensive laboratory testing. Conducting tubing installation risk analysis Reviewing tubing operational, intervention and abandonment scenarios throughout the well life cycle The successful selection and installation of 15Cr was attributed to: The metallurgy selection, tubing procurement and installation process involving multidisciplinary and multifunctional groups both internal and external to PETRONAS. Rigorous testing at two separate laboratory facilities yielding test results which met and exceeded the required performance criteria. A 15Cr tubing make up efficiency of 100%. Impressive performance during operations resulting in a gross running speed of 371 ft/hr versus an average pipe running speed of 810 ft/hr. Use of low penetration dies to prevent slippage during tubing connection make up. This was critical since CRA material is very sensitive to scratching during contact with metal equipment. This potential metal scratching can lead to corrosion. On time delivery of 15Cr tubing from the OCTG provider ensuring sufficient time for preparation of completion accessories prior to offshore load out. Utilization of 15Cr as an alternative to Duplex and Glass Reinforced Epoxy (GRE) materials has also contributed a direct cost saving of 27% to the project.
6
Browne, Alan L., Nancy L. Johnson, and Mark E. Botkin. "Composite Crash Box: Roll Wrap Fabrication and Dynamic Axial Crush Performance." In ASME 2007 International Mechanical Engineering Congress and Exposition. ASMEDC, 2007. http://dx.doi.org/10.1115/imece2007-41143.
Full textAbstract:
A feature of many vehicles is a bolt-on, replaceable front end clip designed to protect the remaining structure in 0° to 30° frontal and offset crashes up to 15 km/hr (ECE-R42, European Danner (AZT), Allianze, VDS, or Thatcham Tests). The principle energy absorbing elements in such front clips are called crash or crush boxes. These are hollow cross section often tubular structures located between the bumper and the front ends of the lower rails. Previous studies of the dynamic axial crush response of carbon fiber reinforced composite tubes suggested that both the mass of the crash box and the amount of overhang of the front end clip could be reduced by switching from a metal to a carbon fiber reinforced composite crash box. The axial dimension of the crash box could theoretically be reduced because of the 20% reduction in stack-up exhibited by composite compared to metal tubular structures. The mass could theoretically be reduced because of the higher energy dissipation capability per unit mass of the carbon fiber composite and the shorter length that would be required. The initiative summarized in this paper was the roll wrapping portion of a one year program intended to prove out these benefits. Specifically, it encompassed the design, roll wrapping fabrication, and dynamic axial crush testing of a carbon fiber composite version of the crash box for a mid-size vehicle. All project goals were met. As first steps crush performance of the baseline Al crash box was determined and requirements were established for the geometry and crush force of the composite crash box, the needed crush force being 70 kN. To achieve the desired crush force levels while reducing mass by 20% compared to Al requires an SEA (specific energy absorption) on the order of 45. Crash box specimens manufactured with the roll wrapping process spanned a wide range of fiber architectures which were chosen based on findings of earlier crush tests of composite tubular specimens. Dynamic axial crush tests were then conducted on these specimens. Through these tests we were successful in identifying combinations of fiber type, fiber architecture, and tube wall thickness that simultaneously satisfied the multiple targets of high crush force, low stack-up (high crush efficiency), and reduced mass.
Reports on the topic "MET-HR"
1
Kim, Joseph J., Samuel Dominguez, and Luis Diaz. Freight Demand Model for Southern California Freeways with Owner–Operator Truck Drivers. Mineta Transportation Institute, October 2020. http://dx.doi.org/10.31979/mti.2020.1931.
Full textAbstract:
This study evaluates the demand for truck-only toll lanes on Southern California freeways with owner–operator truck drivers. The study implemented the stated preference survey method to estimate the value placed by drivers on time, reliability, and safety measures using various scenarios geared towards assessing those values. The project team met face-to-face with owner- operator truck drivers near the Ports of Los Angeles and Long Beach to understand the drivers’ perspectives regarding truck-only toll lanes on Southern California freeways. A data set containing 31 survey responses is obtained and used for statistical data analysis using analysis of variable (ANOVA) and two sample t-tests. The analysis results showed that 75.27% of the owner– operator truck drivers responded are willing to pay toll fees when they choose routes. The tolerated average toll fees are $13.77/ hr and $12.82/hr for weekdays and weekends, respectively. The analysis results also showed that owner–operator truck drivers will take truck-only toll lanes when they take the routes used in four comparisons out of six comparisons according to the three measures such as values of time, reliability, and safety, despite sharing a common origin and destination. The highest toll fee per mile on any day that drivers are willing to pay when the main factor being compared is value of time is $0.31/mile or $18.35/hr. The toll fees associated with reliability and safety measures are $0.30/mile or $8.94/hr and $0.22/mile or $11.01/hr, respectively. These results are meaningful for legislators and transportation agencies as the behaviors and route choice characteristics of owner–operator truck drivers help them better understand the utility and demand for truck-only toll lanes.